glp-1 pipeline news Tracker: Every Drug & Trial (2026) GLP-1 Agonists Market Report 2025-2033,

The findings strongly added to the potential benefit of GLP-1RAs in reducing glaucoma risks

Common examples: J3490 Unclassified drugs (used when no permanent code exists) J3590 Unclassified biologics J1817 Insulin (some combo therapies) Many GLP-1 drugs are processed under a pharmacy benefit rather than a medical benefit

Compounded medications are not FDA-approved and have not been reviewed for safety, effectiveness, or quality as finished products

Common weight loss medications and their coverage status Various medications are approved for weight loss

On average, semaglutide GLP-1 injections achieve a 15% reduction in starting weight when used as part of a comprehensive weight loss plan

Particularly, NASH and CKD are areas where successful drug development has been challenging, and a new effective treatment could be a significant revenue driver